Filtered By:
Condition: Diabetes Mellitus
Drug: Insulin
Procedure: Coronary Angioplasty

This page shows you your search results in order of date.

Order by Relevance | Date

Total 14 results found since Jan 2013.

Short- and Long-term cardiovascular outcomes in insulin-treated versus non-insulin-treated diabetes mellitus patients after percutaneous coronary intervention: a systematic review and meta-analysis
CONCLUSION: Despite a tremendous technical success rate of multi-vessel stenting, people living with diabetes who were being treated with insulin had higher long-term, and short-term mortality rates, MI, TLR, TVR, and stroke compared to people living with diabetes who were being treated with means other than insulin and are more prone to detrimental cardiovascular outcomes.PMID:34906538 | DOI:10.1016/j.ihj.2021.12.004
Source: Indian Heart J - December 15, 2021 Category: Cardiology Authors: Wardah Hassan Javeria Saquib Mahima Khatri Syeda Kanza Kazmi Sohny Kotak Hani Hassan Jawad Ahmed Source Type: research

Canagliflozin Inhibits Human Endothelial Cell Proliferation and Tube Formation
In conclusion, the present study identified canagliflozin as a potent inhibitor of human EC proliferation. The anti-proliferative action of canagliflozin is observed in ECs isolated from both the venous and arterial circulation, and is partly due to the blockade of cyclin A expression. In addition, this study found that canagliflozin inhibits tube formation in cultured ECs and mouse aortic rings. Notably, these actions are specific for canagliflozin and not seen with other SGLT2 inhibitors. The ability of canagliflozin to exert these pleiotropic effects on EC function may contribute to both the adverse and salutary actions...
Source: Frontiers in Pharmacology - April 15, 2019 Category: Drugs & Pharmacology Source Type: research

Prognostic value of glucose metabolism for non-ST-segment elevation infarction patients with diabetes mellitus and single concomitant chronic total occlusion following primary percutaneous coronary intervention
Abstract Glucose metabolism status may play a predictive role in the severity of the complications among patients with type 2 diabetes mellitus (DM). However, few studies have focused on the prognostic value of glycosylated hemoglobin (HbA1c) and Homeostatic Model Assessment 2 for Insulin Resistance (HOMA2-IR) in patients with DM, non-ST-segment elevation infarction (NSTEMI), and single concomitant chronic total occlusion (CTO) following primary percutaneous coronary intervention (PCI). Short- and long-term prognostic value of HbA1c and HOMA2-IR in patients with DM with NSTEMI and single CTO who received primary percutan...
Source: Medicine - November 1, 2017 Category: Internal Medicine Tags: Research Article: Observational Study Source Type: research

Coronary artery bypass grafting versus percutaneous coronary intervention in patients with non ‐insulin treated type 2 diabetes mellitus: a meta‐analysis of randomized controlled trials
ConclusionsIn NITDM patients, our study suggests that CABG surgery is associated with reduced risk of mortality and morbidity, though with increased incidence of stroke compared with PCI. The decision if to have PCI or CABG surgery should factor the risk for stroke of the patients when considering CABG over PCI. Adequately‐powered randomized controlled trials are needed to confirm the results of this meta‐analysis.
Source: Diabetes/Metabolism Research and Reviews - September 1, 2017 Category: Endocrinology Authors: Yushu Wang, Meiqin Wen, Junteng Zhou, Yucheng Chen, Qing Zhang Tags: RESEARCH ARTICLE Source Type: research

Dual Antiplatelet Therapy in Patients with Diabetes and Acute Coronary Syndromes Managed without Revascularization
Conclusions Among NSTE ACS patients managed medically without revascularization, patients with DM had a higher risk of ischemic events that was amplified among those treated with insulin. There was no differential treatment effect with a more potent DAPT regimen of aspirin + prasugrel vs. aspirin + clopidogrel.
Source: American Heart Journal - March 28, 2017 Category: Cardiology Source Type: research

Clinical events beyond one year after an acute coronary syndrome: insights from the RECLOSE 2-ACS study.
CONCLUSIONS: Patients at risk of adverse events beyond 12 months after an ACS may be identified by simple clinical and angiographic characteristics such as age, diabetes, chronic kidney disease, prior MI and multivessel CAD. The risk of adverse events progressively increases with the number of these high-risk features. PMID: 28317790 [PubMed - in process]
Source: EuroIntervention - March 23, 2017 Category: Cardiovascular & Thoracic Surgery Tags: EuroIntervention Source Type: research

Comparison of outcomes after everolimus-eluting stent implantation in diabetic versus non-diabetic patients in the Tokyo-MD PCI study.
CONCLUSIONS: In this all-comer, observational study, the risk of TLR was greater in IRDM compared with non-DM after EES implantation, while the increased risk for TLR from NIRDM did not reach statistical significance. PMID: 26130583 [PubMed - as supplied by publisher]
Source: Journal of Cardiology - June 27, 2015 Category: Cardiology Authors: Konishi Y, Ashikaga T, Sasaoka T, Kurihara K, Yoshikawa S, Isobe M Tags: J Cardiol Source Type: research

High Event Rate After a First Percutaneous Coronary Intervention in Patients With Diabetes Mellitus: Results From the Swedish Coronary Angiography and Angioplasty Registry Coronary Interventions
Conclusions— The prognosis after a first percutaneous coronary intervention is more severe in patients with diabetes mellitus, in particular, in patients treated with insulin, with higher rates of mortality, cardiovascular events, and stent thrombosis over the following 5 years.
Source: Circulation: Cardiovascular Interventions - May 29, 2015 Category: Cardiology Authors: Ritsinger, V., Saleh, N., Lagerqvist, B., Norhammar, A. Tags: Type 2 diabetes, Catheter-based coronary interventions: stents Source Type: research

Long-Term Outcome of PCI Versus CABG in Insulin and Non–Insulin-Treated Diabetic Patients Results From the FREEDOM Trial
BackgroundThe prospective, randomized FREEDOM (Comparison of Two Treatments for Multivessel Coronary Artery Disease in Individuals With Diabetes) trial found coronary artery bypass graft surgery (CABG) was associated with better clinical outcomes than percutaneous coronary intervention (PCI) in patients with diabetes and multivessel disease, managed with or without insulin.ObjectivesIn this subgroup analysis of the FREEDOM trial, we examined the association of long-term clinical outcomes after revascularization in patients with insulin-treated diabetes mellitus (ITDM) compared with patients not treated with insulin.Method...
Source: Journal of the American College of Cardiology: Cardiovascular Interventions - September 15, 2014 Category: Cardiology Source Type: research

Treatment patterns, risk factor control and functional capacity in patients with cardiovascular and chronic kidney disease in the cardiac rehabilitation setting
Conclusion Within a short period of 3–4 weeks, CR led to substantial improvements in key risk factors such as lipid profile, blood pressure, and physical fitness for all patients, even if CKD was present.
Source: European Journal of Preventive Cardiology - August 18, 2014 Category: Cardiology Authors: Voller, H., Gitt, A., Jannowitz, C., Karoff, M., Karmann, B., Pittrow, D., Reibis, R., Hildemann, S. Tags: Original scientific papers Source Type: research

DiaSurg 2 trial - surgical vs. medical treatment of insulin-dependent type 2 diabetes mellitus in patients with a body mass index between 26 and 35 kg/m2: study protocol of a randomized controlled multicenter trial - DRKS00004550
This study aims at investigating whether Roux-en-Y gastric bypass (RYGB) is an efficient treatment for non-severely obese T2DM patients in terms of preventing long-term complications and mortality. Methods: The DiaSurg 2 trial is a multicenter, open randomized controlled trial comparing RYGB including standardized medical treatment if needed to exclusive standardized medical treatment of T2DM (control group). The primary endpoint is a composite time-to-event endpoint (cardiovascular death, myocardial infarction, coronary bypass, percutaneous coronary intervention, non-fatal stroke, amputation, surgery for peripheral athero...
Source: Trials - June 20, 2013 Category: Journals (General) Authors: Hannes KenngottGabriella ClemensMatthias GondanJonas SenftMarkus DienerGottfried RudofskyPeter NawrothMarkus BüchlerLars FischerBeat Müller-Stich Source Type: research

DiaSurg 2 trial - surgical vs. medical treatment of insulin-dependent type 2 diabetes mellitus in patients with a body mass index between 26 and 35 kg/m2: study protocol of a randomized controlled multicenter trial - DRKS00004550
This study aims at investigating whether Roux-en-Y gastric bypass (RYGB) is an efficient treatment for non-severely obese T2DM patients in terms of preventing long-term complications and mortality. Methods: The DiaSurg 2 trial is a multicenter, open randomized controlled trial comparing RYGB including standardized medical treatment if needed to exclusive standardized medical treatment of T2DM (control group). The primary endpoint is a composite time-to-event endpoint (cardiovascular death, myocardial infarction, coronary bypass, percutaneous coronary intervention, non-fatal stroke, amputation, surgery for peripheral athero...
Source: BioMed Central - June 20, 2013 Category: Journals (General) Authors: Hannes G KenngottGabriella ClemensMatthias GondanJonas SenftMarkus K DienerGottfried RudofskyPeter P NawrothMarkus W BüchlerLars FischerBeat P Müller-Stich Source Type: research